Skip to main content
Download PDF

Sex difference in the interrelationship between TNF-α and oxidative stress status in first-episode drug-naïve schizophrenia

Journal of Neuroinflammation volume 18, Article number: 202 (2021) Cite this article

Abstract

Background

Increasing evidence indicates that dysregulated TNF-α and oxidative stress (OxS) contribute to the pathophysiology of schizophrenia. Additionally, previous evidence has demonstrated sex differences in many aspects of schizophrenia including clinical characteristics, cytokines, and OxS markers. However, to the best of our knowledge, there is no study investigating sex differences in the association between TNF-α, the OxS system, and their interaction with clinical symptoms in schizophrenia patients, especially in first-episode drug-naïve (FEDN) patients.

Methods

A total of 119 FEDN schizophrenia patients and 135 healthy controls were recruited for this study. Serum TNF-α, superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), catalase (CAT), and malondialdehyde (MDA) were measured. The Positive and Negative Syndrome Scale (PANSS) was applied to evaluate psychotic symptoms. Two-way ANOVA, partial correlation analysis, and multivariate regression analysis were performed.

Results

A sex difference in MDA levels was demonstrated only in healthy controls (F = 7.06, pBonferroni = 0.045) and not seen in patients. Furthermore, only male patients had higher MDA levels than male controls (F = 8.19, pBonferroni = 0.03). Additionally, sex differences were observed in the association of TNF-α and MDA levels with psychotic symptoms (all pBonferroni < 0.05). The interaction of TNF-α and MDA was only associated with general psychopathology symptom in male patients (B = − 0.07, p = 0.02).

Conclusion

Our results demonstrate the sex difference in the relationship between TNF-α, MDA, and their interaction with psychopathological symptoms of patients with schizophrenia.

Introduction

Schizophrenia is a chronic and severe mental disorder characterized by psychopathological symptoms. The exact mechanisms of schizophrenia are still unclear [1]. Growing evidence suggests that the etiology of schizophrenia may be associated with dysregulated inflammatory pathways and oxidative stress (OxS) [2,3,4].

The activation of the inflammatory system as seen in cytokine activity may be closely related to susceptibility to schizophrenia [5,6,7]. TNF-α is one of the most important pro-inflammatory cytokines and contributes heavily to the pathophysiological process of schizophrenia [8, 9]. The abnormal expression of TNF-α pathway in schizophrenia patients has been well documented in the existing literature [10, 11]. OxS also plays an important role in the pathogenesis of schizophrenia [12]. Cadet and Lohr firstly suggested the role of oxidative mechanisms in schizophrenia in the 1980s [13] and noted the role of oxidative stress in brain dopamine (DA) systems, which are involved in the pathogenesis of schizophrenia [14]. Then, amounting studies have subsequently documented increased OxS and oxidative injury as well as an impaired antioxidant defense system in patients with schizophrenia [15, 16], such as superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), catalase (CAT), and malondialdehyde (MDA). The dopamine system has been one of the most enduring and central hypotheses of schizophrenia. In neurons, DA can be auto-oxidized and causes the production of ROS including DA-quinones and superoxide [17, 18], which was supposed to be involved in the pathophysiology of schizophrenia [19]. On the other hand, previous evidence has suggested that spontaneous abnormal involuntary movements, a part of the symptoms of schizophrenia, might be associated with the pathophysiology of the disease itself without exposure to antipsychotics [20, 21]. The course and the progression of schizophrenia may share the same process with the development of abnormal movements [22].

In addition, it is worthy of note that the OxS system plays a central role through its interaction with the inflammatory system [23]. Reciprocal interactions between OxS and inflammatory systems have been established in previous studies [24, 25]. Previous research has revealed that the mechanism of certain brain developmental disorders caused by the activation of maternal immune systems may be closely related to OxS [26]. The activation of immune cells can secrete OxS mediators, while OxS mediators can also activate and enhance various inflammatory molecules and the immune responses [27]. Additionally, a corresponding relationship between the intensity of immune response and the level of OxS in schizophrenia has been demonstrated in a previous study [28]. Therefore, the relationship between cytokines and OxS mediators must be taken into account. A recent meta-analysis showed that patients with first-episode psychosis (FEP) had lower total antioxidant status, but higher IL6 and TNF-α compared to controls [29]. Correspondingly, our previous studies have also found that TNF-α, the OxS system, and their interaction were involved in the pathophysiology of schizophrenia [30].

Another critical concern is that there are sex differences in many aspects of schizophrenia including incidence rate, onset age, symptoms severity, cognitive function, response to antipsychotics, comorbidities, and outcomes [31,32,33,34,35,36], which may be partly related to psychosocial factors and sex hormones [37]. Furthermore, there are sex differences in levels of cytokines and OxS markers in schizophrenia patients [38,39,40]. For example, Lee et al. demonstrated sex differences in cytokine biomarkers of schizophrenia patients [38], including TNF-α [39]. In addition, previous evidence has shown that female may be more protected against oxidative stress [40], and some preclinical studies have also observed sex differences in oxidative stress markers, including glutathione (GSH), nitrite level, and lipid peroxidation in the hippocampus or striatum in models of schizophrenia [41, 42]. However, other studies found no sex differences in a set of oxidative stress biomarkers, including antioxidant enzymes (GPX and SOD), and MDA levels in either chronic patients [43, 44] or first-episode schizophrenia patients when utilizing a small sample size [45, 46]. These inconsistent results might be attributable to different disease stages or antipsychotics exposure. The sex difference in TNF-α and the OxS system has not yet been adequately explored. In particular, we have determined to the best of our knowledge that there is no current study examining sex differences in the association between TNF-α, the OxS system, and their interrelationship with clinical symptoms in patients with schizophrenia. Thus, this study was undertaken to fill this important knowledge gap.

In this study, first-episode drug-naïve (FEDN) schizophrenia patients were recruited to investigate (1) sex differences in cytokine TNF-α and OxS parameters of FEDN schizophrenia patients and (2) sex differences in the association of TNF-α, the OxS system, and their interaction with clinical symptoms.

Participants and methods

Participants

The protocol for this study was reviewed and approved by Shanghai Mental Health Center and the First Hospital of Shanxi Medical University. Informed consent was obtained from all participants prior to participation in this study. Inclusion and exclusion criteria were detailed in our previous study [30]. Briefly, inclusion criteria included (i) being Han Chinese; (ii) aged from 18 to 45 years old; (iii) meeting diagnostic criteria for schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV); (iv) being a first-episode patient without prior exposure to drugs; and (v) having a duration of illness less than 2 years. Exclusion criteria included (i) individuals with any other major Axis I disorder and (ii) pregnant women.

Healthy controls were recruited based on having no major Axis I disorder diagnosis and no family history of mental disorders. Moreover, participants who had organic brain diseases, ongoing infections, autoimmune disorders, other severe physical diseases, or who received any immunosuppressive treatments were excluded from this study. A total of 119 FEDN patients with schizophrenia and 135 healthy controls were recruited. The demographic data were detailed in our previous study [30]. There were no significant differences in age, sex, education, body mass index (BMI), or smoking behavior between patients and healthy controls [30].

Clinical interview and assessments

The Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID-I/P) was applied by two psychiatrists to screen the participants. Demographic and clinical data were collected by a self-designed questionnaire. The Positive and Negative Syndrome Scale (PANSS) was applied to evaluate psychotic symptoms. Inter-rater concordance of assessments was over 0.8.

Peripheral blood sampling and serum biochemical assays

After fasting overnight for at least 12 h, peripheral venous blood samples of 5 ml volume were collected between 07:00 and 09:00 am. Serum was isolated and was stored at − 80 °C until the assays were performed. The levels of TNF-α, SOD, GSH-Px, CAT, and MDA were measured through Enzyme-linked immunosorbent assays (ELISAs) (R&D Systems, USA). The researchers conducted this experiment according to the manufacturer’s protocol and they were blind to clinical data of samples. All samples were run in duplicate. Random samples were measured to verify the reproducibility of the assay. The intra-assay and inter-assay coefficients of variation were 6.8–7.6% and 6.2–7.4%, respectively.

Statistical analysis

The Kolmogorov-Smirnov test was applied to detect the distribution normality of variables. As serum TNF-α levels distribute non-normally, this measure was transformed to a natural logarithm. Either a Fisher’s exact test or chi-squared test was conducted for nominal variables. Analysis of variance (ANOVA) was conducted for continuous variables.

To investigate sex differences in TNF-α, SOD, GSH-Px, CAT, and MDA levels, two-way ANOVA (diagnosis × sex) was applied, with each index as a dependent variable, setting diagnosis, and sex as fixed factors and adjusting for confounding variables. The main effects of diagnosis, sex, and diagnosis × sex interaction were calculated in each model. Then, an analysis of covariance (ANCOVA) was applied to examine individual univariate effects.

To examine the association between each serum parameter with clinical psychotic symptoms in male and female patients, a partial correlation analysis was performed, controlling for age, BMI, smoking, education, and onset age. Furthermore, to investigate the association of the interaction between TNF-α and OxS parameters with clinical psychotic symptoms in male and female patients, multivariate regression analysis was performed. In this multivariate regression analysis, each PANSS total or subscale score was set as a dependent variable, each interaction (TNF-α × SOD, TNF-α × GSH-Px, TNF-α × CAT, and TNF-α × MDA) as an independent variable, and age, BMI, smoking, education, and onset age were adjusted as covariates. Multiple comparisons were corrected by Bonferroni corrections. Data were analyzed using SPSS version 23.0. The α level of significance was set to p < 0.05 (two-tailed).

Results

Sex difference in demography and clinical characteristics of patients

As shown in Table 1, there were significant sex and diagnosis × sex effects on education (both p < 0.001). An ANOVA demonstrated that male and female patients had lower education than male and female controls, respectively (F = 33.74, p < 0.001; F = 10.28, p = 0.002). Furthermore, male controls had higher education than female controls (F = 106.98, p < 0.001). Education was adjusted for in the following analysis. There was a significant diagnosis × sex effect on BMI (F = 7.44, p = 0.007). An ANOVA showed that male patients had a lower average BMI than female patients (F = 7.22, p = 0.008). BMI was adjusted for in the following analysis.

Table 1 Sex difference in demographic information between healthy controls and schizophrenia patients
Full size table

As shown in Table 2, female patients had an earlier average onset age than male patients (F = 7.22, p = 0.01). Onset age was controlled in the following analysis. There were no significant differences in total score and subscale scores of PANSS between male and female patients (all p > 0.05).

Table 2 Clinical characteristics of male and female patients with schizophrenia
Full size table

Sex difference in levels of TNF-α and OxS parameters between patients and healthy controls

As shown in Fig. 1, a two-way ANOVA that was adjusted for education and BMI demonstrated a main effect of diagnosis on TNF-α, GSH-Px, CAT, and MDA (all p < 0.05), indicating differences in the levels of TNF-α, GSH-Px, CAT, and MDA between patients and healthy controls. There was a main effect of sex on CAT levels indicating sex difference in CAT levels (F = 5.53, p = 0.02). Also, there was a significant diagnosis × sex effect on MDA levels (F = 3.78, p = 0.05), indicating that sex differences in the levels of MDA observed were different between patients and controls. Further, ANCOVA showed that MDA levels were higher in female healthy controls than in male healthy controls (F = 7.06, p = 0.009, pBonferroni = 0.045) and that MDA levels were higher in male patients than in male healthy controls (F = 8.19, p = 0.005, pBonferroni = 0.03). There was no difference in levels of MDA between female patients and female healthy controls (F = 0.01, p = 0.92, pBonferroni> 0.05).

Fig. 1
figure 1

Sex difference in levels of SOD, GSH-Px, CAT, MDA, and TNF-α between patients and healthy controls (mean ± SEM). Male patients (N = 76), male controls (N = 80), female patients (N = 43), and female controls (N = 55). The two-way ANOVA adjusted for education and BMI showed significant main effects of diagnosis on GSH-Px (F = 9.09, p = 0.003), CAT (F = 4. 96, p = 0.03), MDA (F = 4.99, p = 0.03), and TNF-α (F = 4.15, p = 0.04), except SOD (F = 0.01, p = 0.92) (A–E). There was a significant diagnosis × sex effect on MDA levels (F = 3.78, p = 0.05). Then, ANCOVA showed that MDA levels were higher in female healthy controls than in male healthy controls (F = 7.06, p = 0.009, pBonferroni = 0.045), and that MDA levels were higher in male patients than in male healthy controls (F = 8.19, p = 0.005, pBonferroni = 0.03) (A). There was a main effect of sex on CAT levels indicating sex difference in CAT levels (F = 5.53, p = 0.02) (B). SOD, superoxide dismutase; GSH-Px, glutathione peroxidase; CAT, catalase; MDA, malondialdehyde

Full size image

Differences in the relationship between TNF-α and OxS parameters and psychotic symptoms as categorized by sex

As shown in Fig. 2A, controlling for the covariates age, BMI, education, smoking, and onset age, partial correlation showed that TNF-α levels were associated with PANSS positive score in female patients (r = − 0.49, p = 0.002, pBonferroni= 0.008). However, there was no association of TNF-α levels with PANSS positive score in male patients (r = − 0.11, p = 0.36, pBonferroni > 0.05). As shown in Fig. 2B, partial correlation showed that TNF-α levels were associated with PANSS negative score in female patients (r = 0.37, p = 0.02) and in male patients (r = 0.31, p = 0.01). However, after Bonferroni correction, significance remained only for male patients (pBonferroni= 0.04). As shown in Fig. 2C, MDA levels were associated with PANSS general psychopathology scores in male patients (r = − 0.32, p = 0.007, pBonferroni= 0.03), but no association in female patients (r = 0.02, p = 0.92, pBonferroni> 0.05) was found.

Fig. 2
figure 2

The association of TNF-α and MDA levels with psychotic symptoms categorized by sex. A partial correlation analysis was applied. The green dotted curve presents 95% confidence interval. A The association between TNF-α levels and positive symptoms in female patients with schizophrenia (N = 43). TNF-α levels were associated with PANSS positive score in female patients (r = − 0.49, p = 0.002, pBonferroni= 0.008). B The association between TNF-α levels and positive symptoms in male patients with schizophrenia (N = 76). TNF-α levels were associated with PANSS negative score in male patients (r = 0.31, p = 0.01, pBonferroni= 0.04). C The association between MDA levels and general psychopathology symptom in male patients with schizophrenia (N = 76). MDA levels were associated with PANSS general psychopathology scores in male patients (r = − 0.32, p = 0.007, pBonferroni= 0.03)

Full size image

Differences in the relationships of TNF-α and OxS interactions with psychotic symptoms as categorized by sex

To examine sex differences in the association of interaction between TNF-α × SOD, TNF-α × GSH-Px, TNF-α × CAT, or TNF-α × MDA with psychotic symptoms, multivariate regression analysis was applied in male and female patient populations, separately. After controlling for the covariates age, BMI, education, smoking, and onset age, multivariate regression analysis showed that TNF-α × MDA was associated with PANSS general psychopathology scores in male patients (B = − 0.07, t = 2.46, p = 0.02) but not in female patients (B = 0.03, t = 0.81, p = 0.43). Moreover, there was no association of interaction between TNF-α × SOD, TNF-α × GSH-Px, or TNF-α × CAT with any PANSS subscale or total score (all p > 0.05).

Discussion

To the best of our knowledge, this study was the first to examine sex differences in TNF-α, OxS, and their interactions in FEDN schizophrenia patients. The main findings of this study were as follows: (i) There was no sex difference in psychopathology symptoms of the patients. (ii) There were sex differences in MDA levels of healthy controls, but not of schizophrenia patients. MDA levels of female controls were higher than those of male controls, but MDA levels of female patients were similar to those of male patients. (iii) There were sex differences in the association between TNF-α and MDA levels and psychotic symptoms. The interaction between TNF-α and MDA correlated with general psychopathology symptom in male patients only.

Our previous study has shown that FEDN patients had higher TNF-α and MDA levels than in healthy controls. Amounting evidence has revealed the activated TNF pathway in schizophrenia [11]. The immune-neurotoxicity of peripheral TNF-α is associated with psychotic symptoms and cognitive deficits of schizophrenia patients [47]. There are several paths for exchanging cytokines between the periphery and CNS, such as through leakage of the blood-brain barrier (BBB), vagus afferents, and cross-talk between peripheral circulation and central nervous system [48,49,50,51]. Furthermore, previous clinical and preclinical studies have shown that prenatal exposure to infection increased the risk of schizophrenia, and TNF-α decreased the nodes, total dendritic length and inhibit cortical neuron dendrite development, which suggested that brain TNF-α could impair neuronal survival and development [52, 53]. However, the increased TNF-α in the periphery and the brain which acts through indirect and direct pathways may be complex. Klaus et al. reported that both peripheral and brain region-specific increases in TNF could cause abnormal behaviors through different pathways [54]. In addition, dopamine metabolism, involved in the pathophysiology of schizophrenia, is strongly associated with oxidative stress due to its degradation and autooxidation [55]. Besides oxidative stress, DAergic neurons can also release chemoattractants, both of which can lead to microglia activation and inflammatory responses [55].

In this study, we found no sex differences in psychopathological symptoms of FEDN patients, which was consistent with previous studies [56, 57]. However, our results regarding sex differences in symptoms of schizophrenia were not consistent with the current literature. Several studies have shown that males have more negative symptoms than females [58]. González-Rodríguez et al. [59] pointed out that differences in methodology, sample size, and a lack of a systematic and homogenous assessment of psychopathological symptoms may have contributed to the observed discrepancies.

We found that MDA levels of female controls were higher than those of male controls, but those female patients had the same level of MDA as male patients. At present, the results of studies on the differences in MDA levels between men and women are not yet in agreement. However, Kharb et al. [60] found that female healthy controls had higher serum MDA levels than male healthy controls, which corresponds to our findings. Consistent to our findings, several studies have demonstrated no sex difference in MDA levels of first-episode schizophrenia [61] or chronic schizophrenia patients who received stable antipsychotic drugs [62]. The possible reason may be attributable to the following reasons. First, testosterone is an important male sex hormone secreted mainly by male testes. Previous studies have found that testosterone has the effect of antioxidative stress [63, 64]. Wang et al. [65] reported that testosterone supplementation significantly decreased the concentration of MDA in the hippocampus, which explains the higher MDA levels observed in female controls when compared to male healthy controls. Second, in regards to the patients with schizophrenia, increased dopamine in the nigra-striatal pathway is considered to be a driving force of psychosis [66, 67], and the effectiveness of antipsychotics that block the dopamine D2 receptor in relieving hallucinations and delusions is well established [68]. One of the direct dopamine agonists, amphetamine stimulates the release of dopamine [69, 70] and has been reported to inhibit testosterone release in male rats [71, 72]. This suggests that hyperfunction of the dopamine system in schizophrenia patients may inhibit the release of testosterone, which may explain the reasons for having no sex difference in the level of MDA in schizophrenia patients in comparison to controls. Interestingly, Qu et al. [48] recently found that in healthy controls, women had lower MDA levels than men. This contrary result regarding MDA levels in male and female healthy controls might be explained by the characteristics of the samples used. For example, male and female healthy controls had significant differences in age and BMI in that study, which may have influenced the results. In agreement to this, previous reports have shown that oxidative stress is associated with aging and BMI [73]. The level of reactive oxygen species (ROS) increases with the advancement of age [74] and was associated with BMI [75]. In addition, unlike the result of MDA, there was a main effect of sex on CAT levels, but no diagnosis × sex effect indicating sex difference in CAT levels in both patients and controls.

Previous evidence has shown a strong interaction between OxS and the inflammatory system. Astrocytes and microglia can be activated by OxS, causing inflammatory response dysfunction, while the OxS system in nonphagocytic cells can be activated by cytokines including TNF-α [76, 77]. Buelna-Chonta et al. pointed out that the complicated interaction between inflammation and OxS is partly determined by the interaction between the transcription factor Nf-kappaB with Nrf2 [78]. Moreover, previous evidence suggested that neuroinflammation and persistent OxS are critical aspects in the pathophysiology of neurodegenerative diseases [77]. Because of the close relationship between these two systems, Steullet et al. [23] believed that the neuroimmune system, OxS, and glutamatergic system constitute a “central hub,” and that the disturbance of these “hub” systems may lead to the abnormality of parvalbumin interneurons and white matter in patients with schizophrenia through the dysfunction of macro-circuits and micro-circuits. This dysfunction, in turn, affects the symptoms of patients. However, the interaction of TNF-α and OxS on the susceptibility and clinical characteristics of schizophrenia has not been investigated well. We previously reported that the interaction between TNF-α and MDA increased the risk for the occurrence of schizophrenia by 1.61 times, but no significant interactive effects were found on any domain of the PANSS [30]. A recent study also showed that TNF-α was associated with lowered IgM/MDA [47]. In this study, after patients were stratified by sex, we found that the interaction between TNF-α and MDA activities was associated with the severity of general psychopathology in male schizophrenia patients, suggesting that TNF-α and MDA have an interactive effect on the psychopathological symptoms only in male patients. The possible mechanisms may also be associated with testosterone, which can affect the MDA expression. Additionally, testosterone can also affect the expression of inflammatory markers, including TNF-α. Preclinical studies have shown that high testosterone levels during embryonic development have adverse effects on immune function [79]. Furthermore, the use of testosterone significantly reduced the level of inflammatory markers in men [80]. It has been found that the level of TNF-α is higher in adult men with lower testosterone levels [81], while the expression of TNF-α is inhibited by testosterone in men with hypogonadism [82]. A study conducted by Delfino et al. pointed out that TNF-α and NF-kappaB, which may be involved in the interaction between oxidative stress and inflammation [78], could stimulate the expression of androgen receptors in Sertoli cells, and this may be an important mechanism for increasing the response of Sertoli cells to testosterone [83]. This suggests that androgen may have complex interactions with the immune system and OxS, which may explain the reasons for the interaction existence between TNF-α and MDA only in male FEDN schizophrenia patients. Moreover, there were sex differences in the association between TNF-α and MDA levels and psychotic symptoms. The underlying mechanisms should be further investigated in future studies.

Interestingly, there are sex differences in the prevalence of Parkinson’s disease, a disorder that also involves dopaminergic neuron, which is also mainly due to sex hormones [84, 85]. Most importantly, it is well established that methamphetamine exposure can lead to psychotic syndrome similar to schizophrenia mainly through dopaminergic neurotransmission, and repeated methamphetamine administration was used to build an animal model of schizophrenia [86, 87]. Furthermore, oxidative stress and inflammation may both play an important role in the pathophysiology of methamphetamine-associated psychosis [88]. On the other hand, there were also sex-dependent differences in methamphetamine exposure and toxicity [89, 90]. For example, Daiwile et al. demonstrated the sex difference in behavior and gene expression induced by methamphetamine exposure [91].

There were several limitations in this study. Firstly, it is not clear whether peripheral levels of TNF-α and OxS parameters are related to levels present in the brain. However, previous studies suggested that brain immune cells can monitor the peripheral innate immune response through a variety of parallel pathways, including afferent nerves, the humoral pathway, cytokine transporters at the blood-brain barrier, and IL-1 receptors on microvascular cells of the cerebral vein [92]. In addition, central neurons are highly sensitive to OxS exposure, and peripheral OxS can affect the activation of OxS response in brain neurons [93]. There are also extensive interactions between OxS and some other cytokines which should be investigated in future studies.

Conclusion

Our results support the presence of sex differences in the association between TNF-α, MDA, and their interaction with psychopathological symptoms of patients with schizophrenia. Further study with a larger sample size should be conducted to validate our results.

Availability of data and materials

The data that support the findings of this study are available from the corresponding author Zezhi Li upon reasonable request.

Abbreviations

ANOVA:

Analysis of variance

ANCOVA:

Analysis of covariance

BBB:

Blood-brain barrier

BMI:

Body mass index

CAT:

Catalase

DA:

Dopamine

DSM-IV:

Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition

ELISAs:

Enzyme-linked immunosorbent assays

FEDN:

First-episode drug-naïve

FEP:

First-episode psychosis

GSH:

Glutathione

GSH-Px:

Glutathione peroxidase

MDA:

Malondialdehyde

OxS:

Oxidative stress

PANSS:

Positive and Negative Syndrome Scale

ROS:

Reactive oxygen species

SCID-I/P :

Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition

SOD:

Superoxide dismutase

References

  1. van Os J, Rutten BP, Poulton R. Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions. Schizophr Bull. 2008;34(6):1066–82. https://doi.org/10.1093/schbul/sbn117.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Maes M, Sirivichayakul S, Matsumoto AK, Michelin AP, de Oliveira SL, de Lima Pedrao JV, et al. Lowered antioxidant defenses and increased oxidative toxicity are hallmarks of deficit schizophrenia: a nomothetic network psychiatry approach. Mol Neurobiol. 2020;57(11):4578–97. https://doi.org/10.1007/s12035-020-02047-5.

    Article  CAS  PubMed  Google Scholar 

  3. Talukdar PM, Abdul F, Maes M, Binu VS, Venkatasubramanian G, Kutty BM, et al. Maternal immune activation causes schizophrenia-like behaviors in the offspring through activation of immune-inflammatory, oxidative and apoptotic pathways, and lowered antioxidant defenses and neuroprotection. Mol Neurobiol. 2020;57(10):4345–61. https://doi.org/10.1007/s12035-020-02028-8.

    Article  CAS  PubMed  Google Scholar 

  4. Upthegrove R, Khandaker GM. Cytokines, oxidative stress and cellular markers of inflammation in schizophrenia. Curr Top Behav Neurosci. 2020;44:49–66. https://doi.org/10.1007/7854_2018_88.

    Article  CAS  PubMed  Google Scholar 

  5. Wang A, Miller B. Meta-analysis of cerebrospinal fluid cytokine and tryptophan catabolite alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder, and depression. Schizophr Bull. 2018;44(1):75–83. https://doi.org/10.1093/schbul/sbx035.

    Article  PubMed  Google Scholar 

  6. Lesh TA, Careaga M, Rose DR, McAllister AK, Van de Water J, Carter CS, et al. Cytokine alterations in first-episode schizophrenia and bipolar disorder: relationships to brain structure and symptoms. J Neuroinflammation. 2018;15(1):165. https://doi.org/10.1186/s12974-018-1197-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Openshaw RL, Kwon J, McColl A, Penninger JM, Cavanagh J, Pratt JA, et al. JNK signalling mediates aspects of maternal immune activation: importance of maternal genotype in relation to schizophrenia risk. J Neuroinflammation. 2019;16(1):18. https://doi.org/10.1186/s12974-019-1408-5.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Zhang Y, Fang X, Fan W, Tang W, Cai J, Song L, et al. Interaction between BDNF and TNF-alpha genes in schizophrenia. Psychoneuroendocrinology. 2018;89:1–6. https://doi.org/10.1016/j.psyneuen.2017.12.024.

    Article  CAS  PubMed  Google Scholar 

  9. Goldsmith DR, Haroon E, Miller AH, Strauss GP, Buckley PF, Miller BJ. TNF-alpha and IL-6 are associated with the deficit syndrome and negative symptoms in patients with chronic schizophrenia. Schizophr Res. 2018;199:281–4. https://doi.org/10.1016/j.schres.2018.02.048.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry. 2016;21(12):1696–709. https://doi.org/10.1038/mp.2016.3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Hoseth EZ, Ueland T, Dieset I, Birnbaum R, Shin JH, Kleinman JE, et al. A study of TNF pathway activation in schizophrenia and bipolar disorder in plasma and brain tissue. Schizophr Bull. 2017;43(4):881–90. https://doi.org/10.1093/schbul/sbw183.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Sawa A, Sedlak TW. Oxidative stress and inflammation in schizophrenia. Schizophr Res. 2016;176(1):1–2. https://doi.org/10.1016/j.schres.2016.06.014.

    Article  PubMed  Google Scholar 

  13. Cadet JL. Lohr, JB: Free radicals and the developmental pathobiology of schizophrenic burnout. Integr Psychiatry. 1987;5:40–3.

    Google Scholar 

  14. Cadet JL, Brannock C. Free radicals and the pathobiology of brain dopamine systems. Neurochem Int. 1998;32(2):117–31. https://doi.org/10.1016/S0197-0186(97)00031-4.

    Article  CAS  PubMed  Google Scholar 

  15. Emiliani F, Sedlak T, Sawa A. Oxidative stress and schizophrenia: recent breakthroughs from an old story. Curr Opin Psychiatry. 2014;27(3):185–90. https://doi.org/10.1097/YCO.0000000000000054.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Yao JK, Keshavan MS. Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxid Redox Signal. 2011;15(7):2011–35. https://doi.org/10.1089/ars.2010.3603.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Hermida-Ameijeiras A, Mendez-Alvarez E, Sanchez-Iglesias S, Sanmartin-Suarez C, Soto-Otero R. Autoxidation and MAO-mediated metabolism of dopamine as a potential cause of oxidative stress: role of ferrous and ferric ions. Neurochem Int. 2004;45(1):103–16. https://doi.org/10.1016/j.neuint.2003.11.018.

    Article  CAS  PubMed  Google Scholar 

  18. Bitanihirwe BK, Woo TU. Oxidative stress in schizophrenia: an integrated approach. Neurosci Biobehav Rev. 2011;35(3):878–93. https://doi.org/10.1016/j.neubiorev.2010.10.008.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Duan J, Goring HHH, Sanders AR, Moy W, Freda J, Drigalenko EI, et al. Transcriptomic signatures of schizophrenia revealed by dopamine perturbation in an ex vivo model. Transl Psychiatry. 2018;8(1):158. https://doi.org/10.1038/s41398-018-0216-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Gervin M, Browne S, Lane A, Clarke M, Waddington JL, Larkin C, et al. Spontaneous abnormal involuntary movements in first-episode schizophrenia and schizophreniform disorder: baseline rate in a group of patients from an Irish catchment area. Am J Psychiatry. 1998;155(9):1202–6. https://doi.org/10.1176/ajp.155.9.1202.

    Article  CAS  PubMed  Google Scholar 

  21. Pappa S, Dazzan P. Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review. Psychol Med. 2009;39(07):1065–76. https://doi.org/10.1017/S0033291708004716.

    Article  CAS  PubMed  Google Scholar 

  22. Cadet JL, Lohr J, Jeste D. Tardive dyskinesia and Schizophrenic burnout: the possible involvement of cytotoxic free radicals. Handbook of Schizophrenia, Vol 2: Neurochemistry and Neuropharmacology of Schizophrenia. 2015, Edition 1: Chapter 15, Publisher: Elsevier Science Publishers.

    Google Scholar 

  23. Steullet P, Cabungcal JH, Monin A, Dwir D, O'Donnell P, Cuenod M, et al. Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: a "central hub" in schizophrenia pathophysiology? Schizophr Res. 2016;176(1):41–51. https://doi.org/10.1016/j.schres.2014.06.021.

    Article  CAS  PubMed  Google Scholar 

  24. Alboni S, Gibellini L, Montanari C, Benatti C, Benatti S, Tascedda F, et al. N-acetyl-cysteine prevents toxic oxidative effects induced by IFN-alpha in human neurons. Int J Neuropsychopharmacol. 2013;16(8):1849–65. https://doi.org/10.1017/S1461145713000266.

    Article  CAS  PubMed  Google Scholar 

  25. Bakunina N, Pariante CM, Zunszain PA. Immune mechanisms linked to depression via oxidative stress and neuroprogression. Immunology. 2015;144(3):365–73. https://doi.org/10.1111/imm.12443.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Oskvig DB, Elkahloun AG, Johnson KR, Phillips TM, Herkenham M. Maternal immune activation by LPS selectively alters specific gene expression profiles of interneuron migration and oxidative stress in the fetus without triggering a fetal immune response. Brain Behav Immun. 2012;26(4):623–34. https://doi.org/10.1016/j.bbi.2012.01.015.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. McGarry T, Biniecka M, Veale DJ, Fearon U. Hypoxia, oxidative stress and inflammation. Free Radic Biol Med. 2018;125:15–24. https://doi.org/10.1016/j.freeradbiomed.2018.03.042.

    Article  CAS  PubMed  Google Scholar 

  28. Craddock RM, Lockstone HE, Rider DA, Wayland MT, Harris LJ, McKenna PJ, et al. Altered T-cell function in schizophrenia: a cellular model to investigate molecular disease mechanisms. PLoS One. 2007;2(8):e692. https://doi.org/10.1371/journal.pone.0000692.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Fraguas D, Díaz-Caneja C, Ayora M, Hernández-Álvarez F, Rodríguez-Quiroga A, Recio S, et al. Oxidative stress and inflammation in first-episode psychosis: a systematic review and meta-analysis. Schizophr Bull. 2019;45(4):742–51. https://doi.org/10.1093/schbul/sby125.

    Article  PubMed  Google Scholar 

  30. Zhu S, Zhao L, Fan Y, Lv Q, Wu K, Lang X, et al. Interaction between TNF-α and oxidative stress status in first-episode drug-naïve schizophrenia. Psychoneuroendocrinology. 2020;114:104595. https://doi.org/10.1016/j.psyneuen.2020.104595.

    Article  CAS  PubMed  Google Scholar 

  31. Rietschel L, Lambert M, Karow A, Zink M, Muller H, Heinz A, et al. Clinical high risk for psychosis: gender differences in symptoms and social functioning. Early Interv Psychiatry. 2017;11(4):306–13. https://doi.org/10.1111/eip.12240.

    Article  PubMed  Google Scholar 

  32. Mendrek A, Mancini-Marie A. Sex/gender differences in the brain and cognition in schizophrenia. Neurosci Biobehav Rev. 2016;67:57–78. https://doi.org/10.1016/j.neubiorev.2015.10.013.

    Article  PubMed  Google Scholar 

  33. Seeman M. Does gender influence outcome in schizophrenia? Psychiatr Q. 2019;90(1):173–84. https://doi.org/10.1007/s11126-018-9619-y.

    Article  PubMed  Google Scholar 

  34. Huang X, Bao C, Lv Q, Zhao J, Wang Y, Lang X, et al. Sex difference in cognitive impairment in drug-free schizophrenia: association with miR-195 levels. Psychoneuroendocrinology. 2020;119:104748. https://doi.org/10.1016/j.psyneuen.2020.104748.

    Article  CAS  PubMed  Google Scholar 

  35. Zhou Y, Song X, Guo Y, Lang X, Li Z, Zhang XY. Sex differences in metabolic disorder patterns of first-episode drug-naive patients with schizophrenia. Psychoneuroendocrinology. 2020;124:105061. https://doi.org/10.1016/j.psyneuen.2020.105061.

    Article  CAS  PubMed  Google Scholar 

  36. Li Z, Liu X, Xu H, Zhao L, Zhou Y, Wu X, et al. Sex difference in comorbid depression in first-episode and drug-naïve patients with schizophrenia: baseline results from the Depression in Schizophrenia in China (DISC) study. Psychosom Med. 2021, in press. https://doi.org/10.1097/PSY.0000000000000998.

  37. Goldstein JM, Seidman LJ, Makris N, Ahern T, O'Brien LM, Caviness VS Jr, et al. Hypothalamic abnormalities in schizophrenia: sex effects and genetic vulnerability. Biol Psychiatry. 2007;61(8):935–45. https://doi.org/10.1016/j.biopsych.2006.06.027.

    Article  CAS  PubMed  Google Scholar 

  38. Lee EE, Ancoli-Israel S, Eyler LT, Tu XM, Palmer BW, Irwin MR, et al. Sleep disturbances and inflammatory biomarkers in schizophrenia: focus on sex differences. Am J Geriatr Psychiatry. 2019;27(1):21–31. https://doi.org/10.1016/j.jagp.2018.09.017.

    Article  PubMed  Google Scholar 

  39. Ramsey JM, Schwarz E, Guest PC, van Beveren NJM, Leweke FM, Rothermundt M, et al. Distinct molecular phenotypes in male and female schizophrenia patients. PLoS One. 2013;8(11):8. https://doi.org/10.1371/journal.pone.0078729.

    Article  CAS  Google Scholar 

  40. Giordano G, Tait L, Furlong CE, Cole TB, Kavanagh TJ, Costa LG. Gender differences in brain susceptibility to oxidative stress are mediated by levels of paraoxonase-2 expression. Free Radic Biol Med. 2013;58:98–108. https://doi.org/10.1016/j.freeradbiomed.2013.01.019.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Monte AS, Mello BSF, Borella VCM, da Silva AT, da Silva FER, Sousa FCF, et al. Two-hit model of schizophrenia induced by neonatal immune activation and peripubertal stress in rats: study of sex differences and brain oxidative alterations. Behav Brain Res. 2017;331:30–7. https://doi.org/10.1016/j.bbr.2017.04.057.

    Article  CAS  PubMed  Google Scholar 

  42. Célia Moreira Borella V, Seeman M, Carneiro Cordeiro R, Vieira dos Santos J, Romário Matos de Souza M, Nunes de Sousa Fernandes E, et al. Gender and estrous cycle influences on behavioral and neurochemical alterations in adult rats neonatally administered ketamine. Dev Neurobiol. 2016;76(5):519–32. https://doi.org/10.1002/dneu.22329.

    Article  CAS  PubMed  Google Scholar 

  43. Dadheech G, Mishra S, Gautam S, Sharma P. Evaluation of antioxidant deficit in schizophrenia. Indian J Psychiatry. 2008;50(1):16–20. https://doi.org/10.4103/0019-5545.39753.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Padurariu M, Ciobica A, Dobrin I, Stefanescu C. Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics. Neurosci Lett. 2010;479(3):317–20. https://doi.org/10.1016/j.neulet.2010.05.088.

    Article  CAS  PubMed  Google Scholar 

  45. Reyazuddin M, Azmi SA, Islam N, Rizvi A. Oxidative stress and level of antioxidant enzymes in drug-naive schizophrenics. Indian J Psychiatry. 2014;56(4):344–9. https://doi.org/10.4103/0019-5545.146516.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Jordan W, Dobrowolny H, Bahn S, Bernstein HG, Brigadski T, Frodl T, et al. Oxidative stress in drug-naive first episode patients with schizophrenia and major depression: effects of disease acuity and potential confounders. Eur Arch Psychiatry Clin Neurosci. 2018;268(2):129–43. https://doi.org/10.1007/s00406-016-0749-7.

    Article  PubMed  Google Scholar 

  47. Maes M, Sirivichayakul S, Matsumoto AK, Maes A, Michelin AP, de Oliveira SL, et al. Increased levels of plasma tumor necrosis factor-alpha mediate schizophrenia symptom dimensions and neurocognitive impairments and are inversely associated with natural IgM directed to malondialdehyde and paraoxonase 1 activity. Mol Neurobiol. 2020;57(5):2333–45. https://doi.org/10.1007/s12035-020-01882-w.

    Article  CAS  PubMed  Google Scholar 

  48. Ching S, Zhang H, Belevych N, He L, Lai W, Pu XA, et al. Endothelial-specific knockdown of interleukin-1 (IL-1) type 1 receptor differentially alters CNS responses to IL-1 depending on its route of administration. J Neurosci. 2007;27(39):10476–86. https://doi.org/10.1523/JNEUROSCI.3357-07.2007.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Kelley KW, Bluthe RM, Dantzer R, Zhou JH, Shen WH, Johnson RW, et al. Cytokine-induced sickness behavior. Brain Behav Immun. 2003;17(Suppl 1):S112–8. https://doi.org/10.1016/S0889-1591(02)00077-6.

    Article  CAS  PubMed  Google Scholar 

  50. Li Z, Wang Z, Zhang C, Chen J, Su Y, Huang J, et al. Reduced ENA78 levels as novel biomarker for major depressive disorder and venlafaxine efficiency: result from a prospective longitudinal study. Psychoneuroendocrinology. 2017;81:113–21. https://doi.org/10.1016/j.psyneuen.2017.03.015.

    Article  CAS  PubMed  Google Scholar 

  51. Cervellati C, Trentini A, Pecorelli A, Valacchi G. Inflammation in neurological disorders: the thin boundary between brain and periphery. Antioxid Redox Signal. 2020;33(3):191–210. https://doi.org/10.1089/ars.2020.8076.

    Article  CAS  PubMed  Google Scholar 

  52. Nielsen PR, Meyer U, Mortensen PB. Individual and combined effects of maternal anemia and prenatal infection on risk for schizophrenia in offspring. Schizophr Res. 2016;172(1-3):35–40. https://doi.org/10.1016/j.schres.2016.02.025.

    Article  PubMed  Google Scholar 

  53. Gilmore JH, Fredrik Jarskog L, Vadlamudi S, Lauder JM. Prenatal infection and risk for schizophrenia: IL-1beta, IL-6, and TNFalpha inhibit cortical neuron dendrite development. Neuropsychopharmacology. 2004;29(7):1221–9. https://doi.org/10.1038/sj.npp.1300446.

    Article  CAS  PubMed  Google Scholar 

  54. Klaus F, Paterna JC, Marzorati E, Sigrist H, Gotze L, Schwendener S, et al. Differential effects of peripheral and brain tumor necrosis factor on inflammation, sickness, emotional behavior and memory in mice. Brain Behav Immun. 2016;58:310–26. https://doi.org/10.1016/j.bbi.2016.08.001.

    Article  CAS  PubMed  Google Scholar 

  55. Meiser J, Weindl D, Hiller K. Complexity of dopamine metabolism. Cell Commun Signal. 2013;11(1):34. https://doi.org/10.1186/1478-811X-11-34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Ochoa S, Usall J, Cobo J, Labad X, Kulkarni J. Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review. Schizophr Res Treatment. 2012;2012:916198–9. https://doi.org/10.1155/2012/916198.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Bertani M, Lasalvia A, Bonetto C, Tosato S, Cristofalo D, Bissoli S, et al. The influence of gender on clinical and social characteristics of patients at psychosis onset: a report from the Psychosis Incident Cohort Outcome Study (PICOS). Psychol Med. 2012;42(4):769–80. https://doi.org/10.1017/S0033291711001991.

    Article  CAS  PubMed  Google Scholar 

  58. Thorup A, Albert N, Bertelsen M, Petersen L, Jeppesen P, Le Quack P, et al. Gender differences in first-episode psychosis at 5-year follow-up--two different courses of disease? Results from the OPUS study at 5-year follow-up. Eur Psychiatry. 2014;29(1):44–51. https://doi.org/10.1016/j.eurpsy.2012.11.005.

    Article  CAS  PubMed  Google Scholar 

  59. Gonzalez-Rodriguez A, Studerus E, Spitz A, Bugra H, Aston J, Borgwardt S, et al. Gender differences in the psychopathology of emerging psychosis. Isr J Psychiatry Relat Sci. 2014;51:85–92.

    PubMed  Google Scholar 

  60. Kharb S, Ghalaut VS. Plasma lipoperoxides: a preliminary reference range. Indian J Med Sci. 2003;57(3):105–7.

    PubMed  Google Scholar 

  61. Mahadik S, Mukherjee S, Scheffer R, Correnti E, Mahadik J. Elevated plasma lipid peroxides at the onset of nonaffective psychosis. Biol Psychiatry. 1998;43(9):674–9. https://doi.org/10.1016/S0006-3223(97)00282-5.

    Article  CAS  PubMed  Google Scholar 

  62. Akyol O, Herken H, Uz E, Fadillioğlu E, Unal S, Söğüt S, et al. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(5):995–1005. https://doi.org/10.1016/S0278-5846(02)00220-8.

    Article  CAS  PubMed  Google Scholar 

  63. Fanaei H, Karimian S, Sadeghipour H, Hassanzade G, Kasaeian A, Attari F, et al. Testosterone enhances functional recovery after stroke through promotion of antioxidant defenses, BDNF levels and neurogenesis in male rats. Brain Res. 2014;1558:74–83. https://doi.org/10.1016/j.brainres.2014.02.028.

    Article  CAS  PubMed  Google Scholar 

  64. Chisu V, Manca P, Lepore G, Gadau S, Zedda M, Farina V. Testosterone induces neuroprotection from oxidative stress. Effects on catalase activity and 3-nitro-L-tyrosine incorporation into alpha-tubulin in a mouse neuroblastoma cell line. Arch Ital Biol. 2006;144(2):63–73.

    CAS  PubMed  Google Scholar 

  65. Wang L, Pei J, Jia J, Wang J, Song W, Fang X, et al. Inhibition of oxidative stress by testosterone improves synaptic plasticity in senescence accelerated mice. J Toxicol Environ Health Part A. 2019;82(20):1061–8. https://doi.org/10.1080/15287394.2019.1683988.

    Article  CAS  Google Scholar 

  66. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III--the final common pathway. Schizophr Bull. 2009;35(3):549–62. https://doi.org/10.1093/schbul/sbp006.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Howes O, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry. 2012;69(8):776–86. https://doi.org/10.1001/archgenpsychiatry.2012.169.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Seeman P. Targeting the dopamine D2 receptor in schizophrenia. Expert Opin Ther Targets. 2006;10(4):515–31. https://doi.org/10.1517/14728222.10.4.515.

    Article  CAS  PubMed  Google Scholar 

  69. Dluzen DE, Ramirez VD. In vitro progesterone modulation of amphetamine-stimulated dopamine release from the corpus striatum of ovariectomized estrogen-treated female rats: response characteristics. Brain Res. 1990;517(1-2):117–22. https://doi.org/10.1016/0006-8993(90)91016-A.

    Article  CAS  PubMed  Google Scholar 

  70. Dluzen DE, Ramirez VD. In vitro progesterone modulates amphetamine-stimulated dopamine release from the corpus striatum of castrated male rats treated with estrogen. Neuroendocrinology. 1990;52(5):517–20. https://doi.org/10.1159/000125637.

    Article  CAS  PubMed  Google Scholar 

  71. Tsai S, Chen J, Chiao Y, Lu C, Lin H, Yeh J, et al. The role of cyclic AMP production, calcium channel activation and enzyme activities in the inhibition of testosterone secretion by amphetamine. Br J Pharmacol. 1997;122(5):949–55. https://doi.org/10.1038/sj.bjp.0701463.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Tsai S, Chiao Y, Lu C, Doong M, Chen Y, Shih H, et al. Inhibition by amphetamine of testosterone secretion through a mechanism involving an increase of cyclic AMP production in rat testes. Br J Pharmacol. 1996;118(4):984–8. https://doi.org/10.1111/j.1476-5381.1996.tb15496.x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Wonisch W, Falk A, Sundl I, Winklhofer-Roob B, Lindschinger M. Oxidative stress increases continuously with BMI and age with unfavourable profiles in males. Aging Male. 2012;15(3):159–65. https://doi.org/10.3109/13685538.2012.669436.

    Article  CAS  PubMed  Google Scholar 

  74. Schöneich C. Reactive oxygen species and biological aging: a mechanistic approach. Exp Gerontol. 1999;34(1):19–34. https://doi.org/10.1016/S0531-5565(98)00066-7.

    Article  PubMed  Google Scholar 

  75. Keaney J, Larson M, Vasan R, Wilson P, Lipinska I, Corey D, et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol. 2003;23(3):434–9. https://doi.org/10.1161/01.ATV.0000058402.34138.11.

    Article  CAS  PubMed  Google Scholar 

  76. Gonzalez H, Elgueta D, Montoya A, Pacheco R. Neuroimmune regulation of microglial activity involved in neuroinflammation and neurodegenerative diseases. J Neuroimmunol. 2014;274(1-2):1–13. https://doi.org/10.1016/j.jneuroim.2014.07.012.

    Article  CAS  PubMed  Google Scholar 

  77. Solleiro-Villavicencio H, Rivas-Arancibia S. Effect of chronic oxidative stress on neuroinflammatory response mediated by CD4(+)T cells in neurodegenerative diseases. Front Cell Neurosci. 2018;12:114. https://doi.org/10.3389/fncel.2018.00114.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Buelna-Chontal M, Zazueta C. Redox activation of Nrf2 & NF-kappaB: a double end sword? Cell Signal. 2013;25(12):2548–57. https://doi.org/10.1016/j.cellsig.2013.08.007.

    Article  CAS  PubMed  Google Scholar 

  79. Uller T, Olsson M. Prenatal exposure to testosterone increases ectoparasite susceptibility in the common lizard (Lacerta vivipara). Proc Biol Sci. 2003;270(1526):1867–70. https://doi.org/10.1098/rspb.2003.2451.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Maggio M, Basaria S, Ceda G, Ble A, Ling S, Bandinelli S, et al. The relationship between testosterone and molecular markers of inflammation in older men. J Endocrinol Invest. 2005;28(11 Suppl Proceedings):116–9.

    CAS  PubMed  Google Scholar 

  81. Olmos-Ortiz A, García-Quiroz J, Halhali A, Avila E, Zaga-Clavellina V, Chavira-Ramírez R, et al. Negative correlation between testosterone and TNF-α in umbilical cord serum favors a weakened immune milieu in the human male fetoplacental unit. J Steroid Biochem Mol Biol. 2019;186:154–60. https://doi.org/10.1016/j.jsbmb.2018.10.009.

    Article  CAS  PubMed  Google Scholar 

  82. Malkin C, Pugh P, Jones R, Kapoor D, Channer K, Jones T. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab. 2004;89(7):3313–8. https://doi.org/10.1210/jc.2003-031069.

    Article  CAS  PubMed  Google Scholar 

  83. Delfino F, Boustead J, Fix C, Walker W. NF-kappaB and TNF-alpha stimulate androgen receptor expression in Sertoli cells. Mol Cell Endocrinol. 2003;201(1-2):1–12. https://doi.org/10.1016/S0303-7207(03)00005-4.

    Article  CAS  PubMed  Google Scholar 

  84. Gillies GE, Pienaar IS, Vohra S, Qamhawi Z. Sex differences in Parkinson's disease. Front Neuroendocrinol. 2014;35(3):370–84. https://doi.org/10.1016/j.yfrne.2014.02.002.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Bourque M, Morissette M, Di Paolo T. Repurposing sex steroids and related drugs as potential treatment for Parkinson's disease. Neuropharmacology. 2019;147:37–54. https://doi.org/10.1016/j.neuropharm.2018.04.005.

    Article  CAS  PubMed  Google Scholar 

  86. Wearne TA, Cornish JL. A comparison of methamphetamine-induced psychosis and schizophrenia: a review of positive, negative, and cognitive symptomatology. Front Psychiatry. 2018;9:491. https://doi.org/10.3389/fpsyt.2018.00491.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Oka M, Ito K, Koga M, Kusumi I. Changes in subunit composition of NMDA receptors in animal models of schizophrenia by repeated administration of methamphetamine. Prog Neuropsychopharmacol Biol Psychiatry. 2020;103:109984. https://doi.org/10.1016/j.pnpbp.2020.109984.

    Article  CAS  PubMed  Google Scholar 

  88. Chiang M, Lombardi D, Du J, Makrum U, Sitthichai R, Harrington A, et al. Methamphetamine-associated psychosis: clinical presentation, biological basis, and treatment options. Hum Psychopharmacol. 2019;34(5):e2710. https://doi.org/10.1002/hup.2710.

    Article  PubMed  Google Scholar 

  89. Daiwile AP, Jayanthi S, Cadet JL. Sex- and brain region-specific changes in gene expression in male and female rats as consequences of methamphetamine self-administration and abstinence. Neuroscience. 2021;452:265–79. https://doi.org/10.1016/j.neuroscience.2020.11.025.

    Article  CAS  PubMed  Google Scholar 

  90. Bourque M, Dluzen DE, Di Paolo T. Sex and temporally-dependent effects of methamphetamine toxicity on dopamine markers and signaling pathways. Neuropharmacology. 2012;62(7):2363–72. https://doi.org/10.1016/j.neuropharm.2012.02.009.

    Article  CAS  PubMed  Google Scholar 

  91. Daiwile AP, Jayanthi S, Ladenheim B, McCoy MT, Brannock C, Schroeder J, et al. Sex differences in escalated methamphetamine self-administration and altered gene expression associated with incubation of methamphetamine seeking. Int J Neuropsychopharmacol. 2019;22(11):710–23. https://doi.org/10.1093/ijnp/pyz050.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9(1):46–56. https://doi.org/10.1038/nrn2297.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Maciejczyk M, Zebrowska E, Chabowski A. Insulin resistance and oxidative stress in the brain: what's new? Int J Mol Sci. 2019;20(4). https://doi.org/10.3390/ijms20040874.

Download references

Acknowledgement

The authors would like to thank Dr. Xiaoyan Chen, Chenxi Bao, Ruijie Geng, and Yingyi Wang for all of their hard work and significant contributions to the study.

Funding

This study was supported by Shanghai Jiao Tong University Medical Engineering Foundation (YG2016MS48), Excellent Talent Foundation of Shanghai Jiao Tong University School of Medicine (19XJ11006), Clinical Research Project of Shanghai Municipal Health Commission (20204Y0173), and the Outstanding Clinical Discipline Project of Shanghai Pudong (PWYgy2018-10). All funding for this study had no further role in study design, in data analysis, and in the decision to submit the paper for publication.

Author information

Authors and Affiliations

  1. Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, 600 South Wan Ping Road, Shanghai, 200030, China

    Minghuan Zhu, Qinyu Lv & Zhenghui Yi

  2. Clinical Research Center for Mental Disorders, Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University, Shanghai, China

    Minghuan Zhu

  3. Qingdao Mental Health Center, Qingdao University, Qingdao, China

    Zhenjing Liu & Yanhong Guo

  4. Department of Public Health and Informatics, Jahangirnagar University, Savar, Dhaka, Bangladesh

    Mst. Sadia Sultana

  5. Department of Laboratory Medicine, Shanghai Changhai Hospital, Shanghai, China

    Kang Wu

  6. Department of Psychiatry, The First Clinical Medical College, Shanxi Medical University, Taiyuan, China

    Xiaoe Lang

  7. Department of Psychological Medicine, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China

    Xiao Huang

  8. Department of Psychiatry, The Affiliated Brain Hospital of Guangzhou Medical University, 36 Mingxin Road, Guangzhou, 510370, China

    Zezhi Li

Authors
  1. Minghuan Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhenjing Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yanhong Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mst. Sadia Sultana
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kang Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xiaoe Lang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Qinyu Lv
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xiao Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Zhenghui Yi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Zezhi Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Z. L., Z. Y., and X. H. designed the study. M. Z., X. L., X.H., and Q. L. were responsible for recruiting the patients, performing the clinical rating, and collecting the clinical data. K. W. collected the experiment data. Y.G. coordinated the study, collected the literatures, and contributed to data clean. Z. L. and M. Z. did statistical analysis. M. Z, Z.L., and M.S. wrote the manuscript. The authors read and approved the final manuscript.

Corresponding authors

Correspondence to Xiao Huang, Zhenghui Yi or Zezhi Li.

Ethics declarations

Ethics approval and consent to participate

The protocol was approved by Shanghai Mental Health Center and the First Hospital of Shanxi Medical University. Informed consent was obtained from all participants.

Consent for publication

The submission has had all authors’ approval.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhu, M., Liu, Z., Guo, Y. et al. Sex difference in the interrelationship between TNF-α and oxidative stress status in first-episode drug-naïve schizophrenia. J Neuroinflammation 18, 202 (2021). https://doi.org/10.1186/s12974-021-02261-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12974-021-02261-5

Keywords

Journal of Neuroinflammation

ISSN: 1742-2094